Clinical Trial

A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia

Name: A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia — clinical trial record (NCT07681089)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: OP-724-H202

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-06

Trial Details

NCT Number	NCT07681089
Lead Sponsor	Kiminori Kimura, MD Collaborators: Japan Agency for Medical Research and Development, Ohara Pharmaceutical Co., Ltd.
Conditions	Liver Cirrhosis
Enrollment	4 participants
Start Date	2026-09-01
Primary Completion	2027-11-30 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-05